Product Name:
PKG1-pT515+pT517
Product Number:
ab-pk776
Target Full Name: cGMP-dependent protein kinase 1, alpha isozyme
Target Alias: cGK 1 alpha; cGKI-alpha; cGKI-beta; cGMP-dependent protein kinase 1, alpha isozyme; DKFZp686K042; FLJ36117; KGP1A; Kinase PKG1; PGK; PKG; PKG1-alpha; Protein kinase, cGMP-dependent, type I
Product Type Specific: PKG1a protein kinase phosphosite-specific antibody
Antibody Code: PK776
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T515+T517
Protein UniProt: Q13976
Protein SigNET: PKG1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human PKG1a (PRKG1A) sequence peptide Cat. No.: PE-04ARO99
Antibody Immunogen Sequence: FGKK(pT)W(pT)FCG(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues F511 to G521; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T515 and T517 phosphorylation stimulates phosphotransferase activity. These are two of the major in vivo phosphorylation sites in PKG1a (≥4 and ≥13 reports, respectively, from high throughput mass spectrometry studies recorded in PhosphoSitePlus). PKG1a is known to be phosphorylated in vitro at T517 by PKG1 (PRKG1).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.3 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Mouse | Chicken | Zebra fish | Fruit fly | Honey bee | Nematode worm.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 77-83 kDa.
Related Product 1: PKG1 (511-521) pT515+pT517 antibody blocking peptide (Cat. No.: PE-04ARO99)
Related Product 2: PKG1Subtide kinase substrate peptide (Cat. No.: PE-01BIW95)
Related Product 3: PKG1 expression antibody (Cat. No.: AB-NK202-2)
Related Product 4: PKG1a expression antibody (Cat. No.: AB-NK202)
Related Product 5: PKG2 expression antibody (Cat. No.: AB-NK290-1)
Related Product 6: PKG2 expression antibody (Cat. No.: AB-NK290-2)
Scientific Background: PKG1 (PRKG1) is a protein-serine/threonine kinase of the AGC group and PKG family. It is activated by cGMP, which is generated in response to nitric oxide. As a key downstream effector of the nitric oxide (NO)/cGMP signalling pathway, it primarily regulates cardiovascular homeostasis and smooth muscle relaxation. It exists as a homodimer and regulates intracellular calcium levels to inhibit platelet activation, lower blood pressure, and protect against cardiac hypertrophy and fibrosis. Two main isoforms, PKG1α and PKG1β, are generated from the PRKG1 gene, differing in their N-terminal dimerization domains. PKG1α features a leucine/isoleucine zipper (LZ) domain that mediates homodimerization and provides high affinity for cGMP, acting as a crucial regulator in the cardiovascular system. PKG1β contains a distinct N-terminal domain, which can modulate its own activity. Phosphorylation at Thr-59 increases phosphotransferase activity and its affinity for cGMP Phosphorylation at Thr-517 increases phosphotransferase activity. An R177Q mutation in AAT8 results in a constitutively active form of PKG1, which also has reduced cGMP binding. It is highly expressed in smooth muscle, heart, lungs, and the central nervous system (CNS). PKG1 is associated with familial thoracic aortic aneurysm and dissection (AAT8), and is a key target for treating hypertension and cardiac diseases. This description may include information annotated by UniProt and/or Google AI.